Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Urothelial Carcinoma of the Urinary Bladder”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02951767
What this trial is testing

Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

Who this might be right for
Bladder Cancer
Hoffmann-La Roche 119
Testing effectiveness (Phase 2)Study completedNCT01282463
What this trial is testing

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Who this might be right for
Carcinoma of Urinary TractUrethral CarcinomaCarcinoma of Ureter+1 more
Eli Lilly and Company 148
Testing effectiveness (Phase 2)Study completedNCT00009867
What this trial is testing

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Who this might be right for
Recurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerTransitional Cell Carcinoma of the Bladder+1 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT00365157
What this trial is testing

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+4 more
National Cancer Institute (NCI) 171
Early research (Phase 1)Study completedNCT02311101
What this trial is testing

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Who this might be right for
Urinary Bladder Neoplasm
The University of Texas Health Science Center at San Antonio 18
Not applicableStudy completedNCT01135849
What this trial is testing

B-Receptor Signaling in Cardiomyopathy

Who this might be right for
CarcinomasAmyloidosisAnal Cancer+35 more
Daniel Bernstein 99
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)UnknownNCT04878250
What this trial is testing

Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder

Who this might be right for
Transitional Cell CarcinomaBladder Cancer
Queen Mary University of London 49
Early research (Phase 1)Active Not RecruitingNCT06617169
What this trial is testing

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Who this might be right for
Solid Tumor, AdultBladder CancerUrothelial Carcinoma+6 more
Monopar Therapeutics 12
Testing effectiveness (Phase 2)UnknownNCT03824691
What this trial is testing

HARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Who this might be right for
Bladder Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 122
Large-scale testing (Phase 3)Study completedNCT02426125
What this trial is testing

Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
Eli Lilly and Company 530
Large-scale testing (Phase 3)Looking for participantsNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)Ended earlyNCT03288545
What this trial is testing

Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic Neoplasms+4 more
Astellas Pharma Global Development, Inc. 348
Not applicableStudy completedNCT02462239
What this trial is testing

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Who this might be right for
Muscle-invasive Bladder Cancer
Ontario Clinical Oncology Group (OCOG) 292
Testing effectiveness (Phase 2)Ended earlyNCT01042795
What this trial is testing

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

Who this might be right for
Urothelial CarcinomaBladder Cancer
University of Michigan 7
Early research (Phase 1)Active Not RecruitingNCT04963153
What this trial is testing

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+17 more
National Cancer Institute (NCI) 24
Very early researchStudy completedNCT04018053
What this trial is testing

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Who this might be right for
Bladder CancerUrothelial Carcinoma
Brigham and Women's Hospital 16
Testing effectiveness (Phase 2)UnknownNCT01215877
What this trial is testing

Tesetaxel for Previously Treated Patients With Bladder Cancer

Who this might be right for
Carcinoma, Transitional Cell
Genta Incorporated 33
Testing effectiveness (Phase 2)Study completedNCT02351739
What this trial is testing

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Who this might be right for
Metastatic Urothelial Carcinoma
Acerta Pharma BV 78
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Next Page